Učitavanje...
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, and reversible reduction in bone turno...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3387828/ https://ncbi.nlm.nih.gov/pubmed/22767993 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S24239 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|